What is AbCellera Biologics Inc.'s foreign?

AbCellera Biologics Inc. (ABCL) reported foreign of -$50.25K in Q4 2025.

How has AbCellera Biologics Inc.'s foreign changed year-over-year?

AbCellera Biologics Inc.'s foreign decreased by 130.0% year-over-year, from $167.75K to -$50.25K.

What does foreign mean?

The current tax expense or benefit accrued based on income tax regulations in foreign jurisdictions. This captures the tax implications of the company's global footprint and international revenue streams.

AbCellera Biologics Inc. ABCL Foreign

Foreign at other companies

ZymeworksZYME

$224.5K—

BioCryst PharmaceuticalsBCRX

$310K+6.6%

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.84B+59.2%

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CurrentForeignTaxExpenseBenefit.

The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s foreign.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s foreign?: AbCellera Biologics Inc. (ABCL) reported foreign of -$50.25K in Q4 2025.
How has AbCellera Biologics Inc.'s foreign changed year-over-year?: AbCellera Biologics Inc.'s foreign decreased by 130.0% year-over-year, from $167.75K to -$50.25K.
What does foreign mean?: The current tax expense or benefit accrued based on income tax regulations in foreign jurisdictions. This captures the tax implications of the company's global footprint and international revenue streams.